{"nctId":"NCT00730015","briefTitle":"Trial of Linaclotide in Patients With Chronic Constipation","startDateStruct":{"date":"2008-08"},"conditions":["Chronic Constipation"],"count":643,"armGroups":[{"label":"145 μg linaclotide","type":"EXPERIMENTAL","interventionNames":["Drug: Linaclotide"]},{"label":"290 μg linaclotide","type":"EXPERIMENTAL","interventionNames":["Drug: Linaclotide"]},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching Placebo"]}],"interventions":[{"name":"Matching Placebo","otherNames":[]},{"name":"Linaclotide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings\n* Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests\n* Patient meets protocol criteria for CC: reports \\< 3 bowel movements per week and reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation during \\> 25% of BMs\n* Patient demonstrates continued chronic constipation through Pretreatment Period\n* Patient is compliant with IVRS\n\nExclusion Criteria:\n\n* Patient has history of loose or watery stools\n* Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)\n* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility\n* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Spontaneous Bowel Movement (CSBM) Overall Responder","description":"A 12-week CSBM Overall Responder was defined as a patient who for at least 9 of the 12 weeks of the treatment period had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline. A CSBM was defined as a spontaneous bowel movement (SBM) that was associated with a sense of complete evacuation.\n\nAn SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency","description":"The number of CSBMs per week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":"0.17"},{"groupId":"OG001","value":"2.04","spread":"0.17"},{"groupId":"OG002","value":"0.45","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"12-Week Spontaneous Bowl Movement (SBM) Frequency","description":"The number of SBMs per week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.03","spread":"0.21"},{"groupId":"OG001","value":"2.98","spread":"0.21"},{"groupId":"OG002","value":"1.08","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"12-week Change in Stool Consistency","description":"The consistency of each BM was assessed using the 7-point Bristol Stool Form Scale:\n\n1. = separate hard lumps like nuts \\[difficult to pass\\]\n2. = sausage shaped but lumpy\n3. = like a sausage but with cracks on surface\n4. = like a sausage or snake, smooth and soft\n5. = soft blobs with clear-cut edges \\[passed easily\\]\n6. = fluffy pieces with ragged edges, a mushy stool\n7. = watery, no solid pieces \\[entirely liquid\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"0.08"},{"groupId":"OG001","value":"1.84","spread":"0.08"},{"groupId":"OG002","value":"0.58","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"12-week Change in Severity of Straining","description":"Severity of Straining is measured on a 5-point scale, where a value of 1 is \"not at all\" and a value of 5 is \"an extreme amount\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"0.05"},{"groupId":"OG001","value":"-1.15","spread":"0.05"},{"groupId":"OG002","value":"-0.51","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"12-week Change in Abdominal Discomfort","description":"Abdominal discomfort is based on a 5-point scale where a value of l is \"none\" and a value of 5 is \"very severe.\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"0.04"},{"groupId":"OG001","value":"-0.44","spread":"0.04"},{"groupId":"OG002","value":"-0.30","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"12-week Change in Bloating","description":"Bloating was based on a 5-point scale where a value of l is \"none\" and a value of 5 is \"very severe\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"0.04"},{"groupId":"OG001","value":"-0.37","spread":"0.04"},{"groupId":"OG002","value":"-0.22","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"12-week Change in Constipation Severity","description":"Constipation severity was based on a 5-point ordinal scale where a value of l is \"none\" and a value of 5 is \"very severe\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"0.05"},{"groupId":"OG001","value":"-0.81","spread":"0.05"},{"groupId":"OG002","value":"-0.27","spread":"0.05"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":217},"commonTop":["Diarrhea"]}}}